During cellular apoptosis, retinoblastoma protein (RB) is subjected to cleavage near the carboxyl terminus by a caspase-3-like protease. In addition, an heretofore unidenti®ed protease cleaves RB internally, generating fragments of 68 and 48 kDa. Internal cleavage abrogates the ability of RB to associate with E2F. To investigate the mechanism of RB internal cleavage, we developed and employed an in vitro cleavage assay. Incubation of in vitro translated 35 S-RB with apoptotic cell extracts led to RB cleavage at the C-terminus, followed by internal cleavage. The caspase peptide inhibitors z-VAD-FMK or z-DEVD-FMK blocked both cleavage events. Rapid Cterminal and internal cleavage were also observed when recombinant caspase-3 was added to 35 S-RB. Moreover, when caspase-3 was added to nonapoptotic cell extract, ecient internal cleavage of cellular RB was observed. Caspase-mediated internal cleavage occurred following RB residue aspartate 349 in the sequence DSID
Introduction
The retinoblastoma protein (RB), one of the ®rst tumor suppressor proteins identi®ed (Weinberg, 1991) , has been best characterized as a cell cycle regulator (DeCaprio et al., 1989) . The regulatory function of RB is modulated during the cell cycle through phosphorylation of speci®c serine/threonine residues (DeCaprio et al., 1992; Chen et al., 1989; Mihara et al., 1989; Buchovich et al., 1989) . Inactivation of RB through phosphorylation during G1 and S phases results in the release and activation of several transcription factors including members of the E2F family (Chellappan et al., 1991; Chittenden et al., 1991; Bandara and La Thangue, 1991; Bagchi et al., 1991) . Interestingly, the majority of RB binding proteins are regulators of transcription, including E2F-1, c-Abl tyrosine kinase, MyoD, Elf-1, ATF-2 and Mdm2, each of which also has been implicated in the regulation of apoptosis (Wang, 1997) .
The role of RB in apoptosis seems to be primarily one of protection. Homozygous inactivation of the RB gene results in embryonic lethality at 13 ± 15 days gestation concomitant with extensive apoptosis in the developing central nervous system (Lee et al., 1992; Jacks et al., 1992; Clarke et al., 1992) . Fibroblasts derived from RB 7/7 mice show an increased sensitivity to growth factor withdrawal or DNA damage (Almasan et al., 1995) . Reintroduction of functional RB can rescue certain RB-defective cell lines from apoptosis induced by various stimuli (Hass-Kogan et al., 1995; McConkey et al., 1996; Berry et al., 1996) . In addition, it has been shown that treatment of a human oesteosarcoma cell line SAOS-2, which contains a mutant form of RB, with ionizing radiation results in apoptosis (Hass-Kogan et al., 1995) . Transfection of wild-type RB into these cells inhibited apoptosis while transfection of a mutant RB that fails to complex with E2F-1 had no eect. These ®ndings have suggested that RB suppresses apoptosis through inhibition of E2F-1-mediated gene transcription. Other transfection studies, using multiple apoptotic stimuli and cell lines, have con®rmed these results (Berry et al., 1996; Haupt et al., 1995; Kranenburg et al., 1996) .
Additional evidence is accumulating which suggests that E2F-1 is also an important mediator of apoptosis. Deregulated or ectopic expression of E2F-1 or disruption of RB binding can cause aberrant S phase entry and p53-dependent apoptosis (Almasan et al., 1995; Meikranz et al., 1994; Shan et al., 1996; Johnson et al., 1993; Qin et al., 1994) . In E2F-1 knockout mice, it was demonstrated that as the E2F-1 7/7 mice aged, they exhibited lymphoproliferative disorders and a variety of tumors including sarcomas of the reproductive tract, lung tumors and lymphomas (Field et al., 1996; Yamasaki et al., 1996) .
Recent studies have shown that the RB protein is proteolytically cleaved during apoptosis. Three independent studies have con®rmed that the C-terminus of RB is cleaved at the caspase consensus cleavage site DEAD 886 -G; releasing a 42 amino acid peptide and resulting in a protein product that is approximately 5 kDa smaller than full-length RB (reviewed in Tan and Wang, 1998; Janicke et al., 1996; Chen et al., 1997; Tan et al., 1996) . Expression of a C-terminal cleavageresistant mutant did not block Fas-mediated apoptosis of Jurkat T-lymphocytes but could delay TNFainduced cell death (Tan et al., 1996) . However, the role of C-terminal cleavage in apoptosis remains unclear since it was demonstrated that C-terminal cleaved RB was still functional, as it was still able to interact with the E2F-1 transcription factor (Tan et al., 1996) .
We have previously shown that during apoptosis, RB is also cleaved at an interior site, producing fragments of 48 and 68 kDa (An and Dou, 1996; Dou et al., 1997) . RB interior cleavage has been observed in a variety of cell lines in response to a variety of stimuli (etoposide, tamoxifen, roscovitine, sphingosine, staurosporin, anti-Fas antibody) (reviewed in Dou, 1997; Fattman et al., 1998) . Although the enzyme responsible for RB internal cleavage has remained unknown, the cleavage event is inhibited by caspase inhibitors, implicating a caspase protease in the pathway leading to internal cleavage (An and Dou, 1996) . Importantly, cleavage of RB at the internal site, in contrast to C-terminal cleavage, was found to abrogate the ability of RB to bind to E2F-1 (Tan et al., 1996; Fattman et al., 1997) . This suggests that RB internal cleavage may lead to deregulation of the cell cycle and subsequently, apoptosis.
The evidence presented in this report provides a possible link between the cell cycle machinery and the apoptotic cascade. We demonstrate that caspases-3 and -7 can cleave RB internally to generate fragments of 68 and 48 kDa. Moreover, we show that cleavage occurs at a previously uncharacterized cleavage site (DSID 349 ), consistent with a consensus site for caspase-3/-7. We also present evidence that caspase-mediated internal cleavage of RB proceeds more slowly than C-terminal cleavage. These ®nd-ings support a model of sequential two-step cleavage and inactivation of RB, resulting in a novel proapoptotic pathway, during chemotherapy-induced cell death.
Results
Comparison of p48 and p68 fragments found in whole cell extracts with RB fragments produced in vitro To investigate RB degradation during apoptosis, an in vitro system was created to more closely examine the process of RB internal cleavage. Full-length, human RB cDNA was subjected to in vitro transcription/ translation, in the presence of 35 S-methoinine, using rabbit reticulocyte lysates. The resulting 35 S-RB protein was then combined with whole cell extracts from Jurkat cells treated for 4 h with either 50 mM VP-16 (hereafter referred to as apoptotic extract) or DMSO (hereafter referred to as control extract). Both RB interior and C-terminal cleavage was assessed by SDS ± PAGE followed by autoradiography.
In the absence of cell extracts, full-length (Janicke et al., 1996; Chen et al., 1997; Tan et al., 1996) . Also detected were bands of 68 and 48 kDa, consistent with internal cleavage products. A faint band . Samples were electrophoresed on a 10% SDS ± PAGE gel, transferred to nitrocellulose, and visualized by autoradiography. Bands appearing in lanes 1 ± 3 were compared to bands detected by Western blot analysis of apoptotic Jurkat cell extract (lane 4) using an anti-RB monoclonal antibody (G3-245). The G3-245 antibody can recognize full-length RB, C-terminal cleaved RB, and the p48 fragment. In the ®gure, full-length RB, as well as the C-terminal cleaved, p68, p48 and p30 cleavage fragments are indicated of 30 kDa was variably observed. Importantly, the 68 and 48 kDa fragments were not detected following incubation with control extract (Figure 1, lane 2) . In addition, an 80 kDa band of unknown origin was detected after incubation with either apoptotic or control extracts. When 35 S-RB was incubated with control extract, the primary bands detected were fulllength RB (p115) and the 80 kDa band (Figure 1, lane  2) . A minor amount of C-terminal cleavage (generating p112) was also seen in control reactions.
To verify that the p48 and p68 fragments produced in vitro corresponded to RB fragments produced in apoptotic cells, the sizes of the in vitro generated RB fragments were compared with fragments commonly detected by Western blotting of whole cell apoptotic extracts ( Figure 1 , lane 3 vs 4). The antibody used in this case (G3-245) recognizes full-length RB and the p48 cleavage fragment. Comparison of the in vitro and cellular cleavage patterns revealed that the p48 form produced in vitro precisely comigrated with p48 detected by Western blotting of apoptotic cell extracts. Therefore, we concluded that in vitro cleavage of 35 S-RB by apoptotic extracts accurately reproduced RB internal cleavage occurring in whole cells.
Kinetics of p48 and p68 production in vitro and inhibition by caspase peptide inhibitors
In Figure 2 , we examined the kinetics of 35 S-RB cleavage by apoptotic extracts. Bands corresponding to C-terminal cleaved RB (p112), p68, p48, and p30 ®rst appeared after 5 min incubation. Cleavage of 35 S-RB at the C-terminus was essentially complete by 45 min of incubation, and the levels of the C-terminal cleaved protein declined thereafter. By contrast, the levels of p68, p48 and p30 peaked between 1 ± 3 h. This suggests that cleavage of RB at the C-terminus precedes, and may be required for, production of the smaller fragments.
We next determined whether peptide-based caspase inhibitors could abrogate in vitro cleavage of 35 S-RB.
35
S-RB was incubated with apoptotic extract for 4 h in the absence or presence of varying concentrations of z-DEVD-FMK (Figure 3a ) or z-VAD-FMK ( Figure 3b ). The z-DEVD-FMK peptide is an inhibitor of caspase-3-like enzymes, while z-VAD-FMK is a broad spectrum caspase inhibitor. Internal cleavage was completely blocked by 0.01 mM z-DEVD-FMK, while complete inhibition of C-terminal cleavage required 0.1 mM concentration. RB cleavage was less sensitive to z-VAD-FMK, requiring a concentration of 1.0 mM for complete inhibition of interior cleavage and a concentration of 10.0 mM for complete inhibition of Cterminal cleavage (Figure 3b ). Together, these results suggested involvement of a caspase protease in the pathway leading to internal cleavage.
Cleavage of 35 S-RB in vitro by recombinant caspase-3
While experiments with peptide inhibitors suggested involvement of a caspase protease(s) in the pathway S-RB incubated alone (lane 1) or with DMSO extract (lane 2) served as controls. Samples were analysed on a 10% SDS ± PAGE gel, followed by autoradiography leading to RB internal cleavage they did not demonstrate direct internal cleavage of RB by a caspase. We therefore utilized our in vitro cleavage assay to examine the ability of a puri®ed caspase protease to cleave RB. For these experiments, we employed recombinant caspase-3. Caspase-3 is the major cellular executioner in many cell types (Thornberry and Lazebnik, 1998) , and is known to be responsible for C-terminal cleavage of RB (Chen et al., 1997) . In Figure 4 , puri®ed caspase-3 (100 ng) was added to 35 S-RB substrate and evidence of C-terminal and interior cleavage was assessed. Cleavage of 35 S-RB at the C-terminus was clearly detected and was almost complete within 1 min of caspase-3 addition (Figure 4 , lane 5). The levels of Cterminal cleaved RB decreased over time and were undetectable by 1 h of incubation (Figure 4, lane 9) .
Importantly, incubation of 35 S-RB with recombinant caspase-3 also resulted in the production of RB fragments of 48 and 68 kDa. The p48 and p68 fragments produced by caspase-3 precisely comigrated with p48 and p68 produced by apoptotic extracts (Figure 4 , lane 3). This strongly suggests that a caspase-3-like enzyme in apoptotic cells or extracts is responsible for RB internal cleavage. The levels of p48 and p68 produced by caspase-3 peaked between 5 and 15 min, but remained somewhat elevated throughout the 4 h experiment. As suggested by Figure 2 , this again indicated that C-terminal cleavage precedes, and may be required for, internal cleavage.
In addition to p48 and p68, several additional fragments in the range 26 ± 31 kDa were also generated by caspase-3. These fragments were ®rst detected after 5 min (although more prominently after 15 min), and their levels continued to increase thereafter. Perhaps either p48 or p68 are subjected to additional degradation by caspase-3, resulting in the production of these smaller fragments.
Caspase-3-mediated internal cleavage of cellular RB In addition to the cleavage of 35 S-RB by caspase-3, we also examined whether caspase-3 could mediate internal cleavage of cellular RB protein. Recombinant caspase-3 was incubated with non-apoptotic whole cell extracts for either 5 min or 4 h, and Western blotting ( Figure 5 ) was used to assess production of C-terminal and p48 cleavage fragments. Incubation with recombinant caspase-3 led to production of both C-terminal and p48 cleavage fragments of cellular RB ( Figure 5 , lanes 2 and 4). This further supports the notion that caspase-3 or a caspase-3-like enzyme may be responsible for RB internal cleavage in apoptotic cells. Also, it is interesting to note that the p30 fragment, undetectable after 5 min, is observed following 4 h incubation (compare lanes 2 and 4). This indicates that the p30 fragment arises from further cleavage of p48.
Can other caspases cleave RB?
We next sought to determine whether caspases other than caspase-3 can cleave RB internally. For this purpose, RB interior cleavage was examined in MCF-7 breast cancer cells, which are devoid of caspase-3 (Kurokawa et al., 1999) . Figure 6a demonstrates that pro-and active forms of caspase-3 were not detected in untreated or VP-16-treated MCF-7 cells. By contrast, abundant caspase-3 was detected in Jurkat cells under the same conditions (Figure 6a ). Figure 6b demonstrates that, although MCF-7 cells lack caspase-3, RB Samples were electrophoresed on a 10% SDS ± PAGE gel, followed by autoradiography. Full-length RB, as well as Cterminal cleaved, p68 and p48 fragments are indicated. In addition, several smaller fragments were detected at later timepoints and may represent further degradation products of the p68 and p48 fragments Figure 5 Cleavage of cellular RB protein by recombinant caspase-3. Non-apoptotic cellular extracts (20 mg) were incubated in the absence (lanes 1 and 3) or presence (lanes 2 and 4) of recombinant caspase-3 (0.1 mg). Incubations were carried out at 378 for 5 min (lanes 1 and 2) or 4 h (lanes 3 and 4). Samples were electrophoresed on a 10% SDS ± PAGE gel, transferred to nitrocellulose, then probed with anti-RB monoclonal antibody G3-245 as described in Materials and methods Figure 6b, lane 3) . This indicates that caspases other than caspase-3 can also act upon RB to produce internal cleavage during apoptosis. The same can be said for C-terminal cleavage of RB, since C-terminal cleavage was also observed in MCF-7 cells.
Oncogene
Another likely candidate as an RB cleaving enzyme is caspase-7. Together, caspase-3 and -7 comprise the caspase-3 subfamily of caspase proteases (Alnemri et al., 1996) . Both enzymes recognize and cleave following the consensus cleavage site DXXD. In Figure 7a the kinetics of caspase-3 and -7 activation, as well as RB internal cleavage, were examined in VP-16-treated Jurkat cells. As indicated by the appearance of processed active subunits, activation of both caspase-3 and -7 was ®rst detected after 4 h of treatment. RB internal cleavage, however, was not detected until 5 h. The fact that caspase-7 activation preceded RB internal cleavage supported the possibility that this enzyme also may cleave RB. To directly test this possibility, recombinant caspase-7 was added to in vitro translated 35 S-RB ( Figure 7b ). As shown, caspase-7, like caspase-3, cleaved RB internally to generate fragments of 68 and 48 kDa. By contrast, recombinant caspases-6 and -8 failed to cleave RB internally. Caspase-6, similar to caspases-3 and -7, is an executioner caspase, while caspase-8 is an initiator caspase. Both caspase-6 and -8 recognize consensus cleavage sites dierent from the DXXD site motif recognized by caspase-3 and -7. Taken together, our data indicate that RB internal cleavage is mediated by members of the caspase-3 subfamily, namely caspase-3 and -7.
The RB internal cleavage site
The above results showed that caspase-3 and -7 can cleave RB (in vitro translated or cellular) internally to generate p48 and p68 fragments resembling those found in apoptotic cells. We then sought to determine the precise RB internal cleavage site utilized by caspase-3/-7. Previous studies have shown that the p48 fragment of RB contains amino-terminal sequences, while the p68 fragment contains carboxylterminal sequences (Fattman et al., 1997) . Analysis of the RB protein sequence revealed a single caspase-3/-7 consensus cleavage site whose cleavage would result in production of a p48 N-terminal fragment and a p68 Cterminal fragment. This potential cleavage site, DSID 349 , ®t the DXXD consensus form for caspase-3 and -7 enzymes.
To determine whether RB internal cleavage occurred at the DSID 349 site, we used site-directed mutagenesis to generate a D349A mutant. In vitro translated mutant- 
Discussion
In this study, we developed and employed an in vitro 35 S-RB cleavage assay to investigate apoptosis-associated RB internal cleavage. This assay, which utilized in vitro translated 35 S-RB as substrate, accurately reproduced RB C-terminal and internal cleavage observed in apoptotic cells. We used this assay to: (1) compare the kinetics of RB internal cleavage with RB C-terminal cleavage; (2) determine the enzyme(s), or class of enzymes, responsible for RB internal cleavage; and (3) identify the RB internal cleavage site. Incubation of 35 S-RB with apoptotic cell extracts resulted in cleavage at the C-terminus, as well as cleavage at the internal site to generate fragments of 48 and 68 kDa. Both C-terminal and internal cleavage were inhibited in this assay by z-DEVD-FMK, an inhibitor of caspase-3-like enzymes, and by z-VAD-FMK, a pancaspase inhibitor. These results con®rmed earlier reports of caspase-3-mediated RB C-terminal cleavage, and pointed to the possible involvement of a caspase-3-like enzyme in RB interior cleavage.
We tested the potential of caspase-3 to act as an RB internal cleavage enzyme using the in vitro cleavage assay. These experiments showed that recombinant caspase-3 cleaved both 35 S-RB and cellular RB protein at the C-terminus. In addition, caspase-3 cleaved both substrates internally to generate the characteristic p48 and p68 fragments observed in apoptotic cells. A single caspase-3/-7 consensus cleavage site (DXXD) was found in the RB sequence that would generate S-RB was incubated alone (lane 1) or with recombinant caspases-3, -6, -7, or -8 (0.1 mg enzyme/reaction). Reactions were electrophoresed on a 10% SDS ± PAGE gel, transferred to nitrocellulose, and exposed to ®lm. The locations of the p68 and p48 RB internal cleavage products are indicated by arrows. Internal cleavage was observed following incubation with either caspase-3 or -7, but not caspase-6 or -8 4) , with 0.1 mg of caspase-3 (lanes 2 and 5), or with 0.1 mg of caspase-7 (lanes 3 and 6) for 2 h at 378C. The fulllength RB and C-terminal cleaved RB are shown. Arrows indicate the p68 and p48 internal RB fragments characteristic of apoptosis. Bands corresponding to p68 and p48 were detected in lanes containing wild-type RB but not mutant RB. By contrast, the C-terminal cleaved form of RB was detected with both wildtype and mutant proteins appropriately-sized p48 and p68 fragments, and mutation of this site (DSID 349 to DSIA 349 ) served to abolish internal cleavage. These ®ndings implicated caspase-3 as the RB internal cleavage enzyme and DSID 349 as the internal cleavage site. However, it was also noted that RB internal cleavage occurs in caspase-3-de®cient MCF-7 cells induced to undergo apoptosis. This raised the possibility that other similar enzymes may contribute to RB internal cleavage, or may compensate for caspase-3 in the absence of this enzyme. Indeed, caspase-7, which together with caspase-3 comprises the caspase-3 subfamily, was found capable of cleaving RB at the C-terminus and also internally. At this stage we cannot conclude with certainty which enzyme, caspase-3 or -7, cleaves RB in apoptotic cells. Perhaps caspase-7 simply compensates for caspase-3 in the absence of this enzyme. Alternatively, caspase-7 may be the primary enzyme responsible for either C-terminal or internal cleavage. Yet another possibility is that both enzymes play a role in RB cleavage in apoptotic cells. Attempts to resolve these issues will bene®t from studies of RB cleavage in caspase-7-de®cient cells.
We also observed that internal cleavage of RB was delayed relative to C-terminal cleavage. This was true irrespective of the source of cleavage activity (recombinant caspase-3 or apoptotic cell extract). It is noteworthy that following C-terminal cleavage, RB retains the ability to bind E2F-1 transcription factor (Tan et al., 1996) . However, internal cleavage abolishes the E2F-1 binding capacity of RB (Fattman et al., 1997) . This suggests a model for the fate of RB during apoptosis (Figure 9 ). In this model, caspase-3 and -7 are activated during apoptosis execution and cleave RB near the C-terminus. At this point, RB is not functionally inactivated since it can still bind E2F-1. However, cleavage at the C-terminus may alter the conformation of RB, exposing the DSID 349 internal cleavage site. Caspase-3 or -7 then cleaves RB internally to generate fragments of 48 and 68 kDa. Processing of RB at the internal site would render the molecule functionally inactive, causing release of E2F-1. The liberation of E2F-1 would then serve to promote apoptosis in the cell. The proapoptotic activity of E2F-1 has been demonstrated in several studies linking deregulation of E2F-1 with induction of apoptosis (Almasan et al., 1995; Meikranz et al., 1994; Shan et al., 1996; Johnson et al., 1993; Qin et al., 1994) . Further testing of this model will be needed to fully understand the functional inactivation of RB in apoptotic cells. Of particular interest, it will be important to determine whether C-terminal cleaved RB is the only substrate for internal cleavage, or whether full-length RB can also be cleaved internally.
Materials and methods

Chemicals and other reagents
35
S-Methionine was obtained from Amersham (Piscataway, NY, USA). pBKS plasmid was obtained from Stratagene (La Jolla, CA, USA). The pLRBRNL plasmid (Huang et al., 1988) was a generous gift from Dr WH Lee (University of Texas Institute of Biotechnology, San Antonio, TX, USA). Dithiotheitol (DTT) and Isopropyl-b-D-thiogalactopyranoside (IPTG) were purchased from Boehringer Mannheim (Indianapolis, IN, USA). Recombinant caspases were from BD PharMingen (San Diego, CA, USA). 5-bromo-4 chloro-3 indolyl-b-D-galactosidase (X-gal) was purchased from Research Products International (Prospect, IL, USA). Etoposide, tamoxifen and all other chemicals were purchased from Sigma (St. Louis, MO, USA).
Cell culture
Human Jurkat T-leukemic cells and MCF-7 breast cancer cells were grown in RPMI 1640 media supplemented with 10% fetal bovine serum (Gibco/BRL), 100 U/ml penicillin (Gibco/BRL) and 100 mg/ml streptomycin (Gibco/BRL). Cells were grown at 378C under an atmosphere of 5% CO 2 .
Drug treatments
Etoposide (VP-16) was dissolved in DMSO and stored in aliquots at 7208C. Cells were plated at a concentration of 5610 6 cells/ml and treated with the appropriate concentration of drug. The ®nal concentration of DMSO, however, never exceeded 0.2%. Unless otherwise indicated, controls were treated with equivalent concentrations of DMSO. The peptide inhibitors z-DEVD-FMK and z-VAD-FMK were also dissolved in DMSO and stored at 7208C. 
Preparation of whole cell extracts
Whole cell extracts were prepared for use in in vitro cleavage reactions, or for use in Western blotting experiments. To prepare whole cell extracts, 20610 6 Jurkat cells were pelleted, washed twice in PBS, and homogenized in 20 ± 50 ml of lysis buer (50 mM Tris (pH 8.0), 5 mM EDTA, 150 mM NaCl, 0.5% NP-40). After 30 min incubation at 48C with constant mixing, cell lysates were cleared and the supernatants collected as whole cell extracts. Extracts were stored at 7808C either in lysis buer alone, or in lysis buer plus sample buer (143 mM Tris pH 6.8, 4.6% SDS, 23% glycerol, 0.1% bromophenol blue, 3% b-mercaptoethanol).
Western blot analysis
Puri®ed mouse monoclonal antibody to human RB protein (G3-245) was purchased from PharMingen (San Diego, CA, USA). Rabbit anti-caspase-3 polyclonal antibody and mouse anti-caspase-7 monoclonal antibody were also purchased from BD PharMingen (San Diego, CA, USA). Horseradishperoxidase conjugated anti-mouse or anti-rabbit IgG antibodies were purchased from Promega (Madison, WI, USA). For Western blotting, whole-cell extracts (50 mg protein/lane unless otherwise indicated) were electrophoresed on SDS ± PAGE gels and transferred to nitrocellulose membranes. The protein-bound membranes were subjected sequentially to blocking (5% non-fat milk dissolved in PBS containing 0.03% Tween) for 1 h, incubation with primary antibody in 1% milk/PBS-Tween for 1 h, and incubation with the appropriate horseradish peroxidase (HRP)-conjugated secondary antibody in PBS-Tween for 1 h. All incubations were performed at room temperature. Protein-bound antibodies were detected by enhanced chemiluminescence (NEN, Boston, MA, USA) on autoradiographic ®lm (Eastman Kodak, Rochester, NY, USA), according to the instructions of the manufacturer. Dilutions of the primary antibodies were as follows: G3-245 (1 : 2000) , and anti-caspase-3 (1 : 3000). Secondary antibodies were used at dilutions recommended by the manufacturer (Promega).
Subcloning of the human RB cDNA into pBluescript
Full-length RB cDNA was removed from pLRBRNL plasmid (Huang et al., 1988) by digestion with HindIII. The 4.9 kb RB cDNA fragment was then subcloned into the HindIII site of Bluescript KS vector (pBKS). Plasmid DNA was prepared using the Qiagen midi-prep system (Valencia, CA, USA).
Site-directed mutagenesis of human RB cDNA PCR-based site-directed mutagenesis was used to generate a D 349 to A 349 mutation of the full-length RB protein. The following primers (obtained from Gibco/BRL) were used to create the mutation: huRB-A (5' primer), CATGAATG-TAATATAGATGAGGTGA; huRB-B (internal mutant primer), CTCTTTCAGACTGATTCTATAGCCAGTTTT-GAAACACAGA; huRB-C (internal mutant primer), CTCTGTGTTTCAAAACTGGCTATAGAATCAGTATG -AAGAGT; huRB-D (3' primer), CCAGAATCAA-GATTCTGAGATGTA. The PCR reactions resulted in the ampli®cation of a 1.1 kb internal RB fragment containing the mutation. For replacement of wild-type RB fragment with the mutant fragment, pBKS/RB (full-length, wild-type) was digested with BglII allowing removal of a 1.1 kb fragment surrounding the mutation site. The PCR fragment containing the D 349 to A 349 mutation was then cleaved with BglII and ligated into the BglII digested vector. The resulting plasmid, pBKS/RBmut, was transformed into DH5a bacteria (Gibco/BRL, Gaithersburg, MD, USA), and puri®ed plasmid DNA was obtained.
In vitro
35
S-RB cleavage assay 35 S-RB was produced by in vitro transcription/translation using the Promega TNT rabbit reticulocyte lysate system (Madison, WI, USA). Brie¯y, rabbit reticulocyte lysate was combined with 1 mg of plasmid containing either the fulllength RB cDNA (pBKS/RB) or a full-length RB cDNA containing a D 349 to A 349 mutation (pBKS/RBmut) in the presence of S-RB (D349A) was combined with 15 ml of reaction buer (20 mM HEPES pH 7.4, 2 mM DTT and 10% glycerol) and one of the following enzyme sources: 1 ml (50 mg) of whole cell extract (from Jurkat cells treated with DMSO or 50 mM VP-16 for 4 h) or 1 ml (0.1 mg) recombinant caspase-3 or -7. The samples were incubated at 378C for up to 4 h, after which 20 ml of sample buer was added to stop the reaction. The reaction products were then electrophoresed on SDS ± PAGE gels, transferred to nitrocellulose, and detected by autoradiography. Peptide inhibitors were added simultaneously with the enzyme source to reaction mixtures. A modi®cation of this assay was used to generate Figure 5 . In this experiment, non-apoptotic Jurkat whole cell extract (50 mg) was incubated in 15 ml reaction buer with 1 ml recombinant caspase-3 for 5 min or 4 h. Samples were then analysed by SDS ± PAGE followed by Western blotting with G3-245.
Abbreviations RB, retinoblastoma protein; z-VAD-FMK, z-Val-Ala-Aspuoromethyl-ketone; z-DEVD-FMK, z-Asp-Glu-Val-Aspuoromethyl-ketone; DTT, dithiothreitol; DMSO, dimethylsulfoxide; PBS, phosphate-buered saline; HRP, horseradish peroxidase; pBKS, Bluescript KS vector; PAGE, polyacrylamide gel electrophoresis; etoposide 
